Dynavax Technologies Corporation (LON:0IDA)

Market Cap	1.05B
Revenue (ttm)	221.46M
Net Income (ttm)	21.81M
Shares Out	n/a
EPS (ttm)	0.16
PE Ratio	48.36
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72
Average Volume	511
Open	10.70
Previous Close	10.96
Day's Range	10.70 - 10.70
52-Week Range	9.50 - 15.15
Beta	1.26
RSI	40.36
Earnings Date	May 5, 2025

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the pr...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1996
• Employees: 405
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IDA

Financial Performance

Financial numbers in USD